Manufacturer Recalls Nasal Spray Contaminated with Burkholderia cepacia Complex
MIAMI- The Centers for Disease Control and Prevention (CDC) has been notified of a voluntary recall of over-the-counter oxymetazoline HCl 0.05 percent nasal spray because of intrinsic contamination with Burkholderia cepacia complex. The nasal spray is distributed as "Major Twice-A-Day 12 Hour Nasal Spray." The manufacturer, Propharma Inc., of Miami, has recalled lot No. K4496, released in November 2003, with an expiration date of October 2006.
Preliminary molecular epidemiology indicates that isolates related to the strain found in the nasal spray have been recovered from patients in multiple states. Clinicians should be aware that patients using product from this lot number might have been exposed to B. cepacia complex. Patients with underlying lung disease (especially cystic fibrosis) might be at increased risk for severe infections with B. cepacia complex. Cases of B. cepacia complex infection or colonization associated with use of this product should be reported to the local or state health department and the CDC at (800) 893-0485.
Source: CDC
Hiding in Plain Sight: The Most Harmful and Costly Hospital-Acquired Infection
February 5th 2025Nonventilator hospital-acquired pneumonia (NV-HAP) is a deadly, overlooked infection impacting patient outcomes. With new diagnostic tools and prevention strategies, hospitals must prioritize oral hygiene to reduce risk.
Gag Order Puts Public Health at Risk, APIC Urges Immediate Action
February 4th 2025APIC warns that the HHS gag order on CDC communications endangers public health, delaying critical infection updates and weakening outbreak response amid rising tuberculosis, avian flu, Ebola, and measles threats.
